## -online.com **QENOMICS**





## **Human POLA2 CRISPR gRNA in Lenti Particles**

| Overview              |   |
|-----------------------|---|
| Quantity:             | 300 μL  |
| Gene:                 | POLA2   |
| Species:              | Human   |
| Insert:               | gRNA  |
| Vector:               | Lentiviral Vector   |
| Application:          | Protein Expression (PExp), Genome Editing with Engineered Nucleases (GEEN)                                      |
| Product Details       |   |
| Purpose:              | Individual gRNA against POLA2 in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (Cas9 required separately) |
| Vector Backbone:      | pLenti-U6-sgRNA-PGK-Neo   |
| Promoter:             | U6 Promoter, PGK Promoter   |
| Selectable Marker:    | Neomycin  |
| Bacterial Resistance: | Ampicillin  |
| Expression Type:      | Stable, Transient   |
| Sequence:             | Sequence available upon placing order   |
| Specificity:          | GRNAs are designed for use with Cas9 Nuclease only.   |
| Components:           | Lentiviral particles with an individual gRNA (300 $\mu$ L) for a specific sequence of POLA2                     |
| Target Details        |   |
| Gene:                 | POLA2   |
| Alternative Name:     | POLA2 (POLA2 Products)  |
| NCBI Accession:       | NM_002689   |

## **Application Details**

| Application Notes: | Recommended for quality control: Restriction Enzyme Digest and Sequencing                        |
|--------------------|--|
| Restrictions:      | For Research Use only  |
| Handling           |  |
| Format:            | Viral Particles  |
| Storage:           | -80 °C   |
| Expiry Date:       | 12 months  |
| Publications       |  |
| Product cited in:  | Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, ( |